Announcements

According to the World Health Organization, cancer is a leading cause of mortality and accounted for approximately 10 million deaths in 2020. Therefore, continued research regarding understanding, diagnosing, and treating cancer is a global priority. The ever-evolving field of oncology spans innovations and discoveries in tumor biology, immunotherapy, targeted treatments, early detection, and personalized medicine.

The mission of MDPI’s cluster of oncology-related journals is to publish high-impact research with potential to redefine cancer treatment and care. Addressing topics from solid tumors to hematologic malignancies, from rare cancers to novel therapeutics, these journals provide a dynamic platform for groundbreaking discoveries and clinical advancements that shape the future of oncology.

The four participating journals are as follows:

• Cancers (ISSN: 2072-6694) focuses on publishing high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics. In particular, it showcases the most seminal studies in the rapidly growing areas of immunology, immunotherapy, and tumor microenvironment research. Cancers is led by its Editor-in-Chief, Prof. Dr. Samuel C. Mok;
• Current Oncology (ISSN: 1718-7729) is dedicated to advancing cancer care and therapy via publishing clinically relevant research with direct applications to oncology practice. Since its establishment in 1994, the journal has played an important role in disseminating new knowledge across the entire cancer care continuum, spanning the prevention, early detection, and diagnosis of cancer; treatment, including systemic therapy, radiation therapy, and surgery; supportive care; and survivorship care. Additionally, it highlights the critical role of biomarkers and biomarker-driven research in guiding personalized oncology. Affiliated with several key cancer societies, Current Oncology provides a global platform to share scientific progress in oncology. The journal is led by its Editor-in-Chief, Prof. Dr. Shahid Ahmed;
• Onco (ISSN: 2673-7523) functions as a scientific forum integrating novel preclinical, translational, and clinical cancer research and is focused on (but not limited to) the following topics: cancer cell signaling; cancer genetics and molecular targets; cancer epigenetics and heterogeneity; carcinogenesis and cancer evolution; microbiomes and cancer; cancer metabolomics; cancer biomarkers; cancer dormancy; novel targeted and immune cancer therapies; randomized clinical trials; oncotargets; cancer therapies; and clinical reports proposing novel therapeutic regimens. Onco is led by its Editor-in-Chief, Dr. Constantin N. Baxevanis;
• Targets (ISSN: 2813-3137) is centered on, but not limited to, discovering novel molecules which act as diagnostic biomarkers and therapeutic targets, establishing new bionic recognition systems for biosensing and bioimaging, developing novel approaches for biomarker detection, related applications of biological interaction monitoring and targeted therapy, designing new signal amplification strategies for biosensing and cellular or in vivo imaging, utilizing molecular recognition for single-molecule or single-cell analysis, elucidating new pathways or mechanisms in disease development and progression, and synthesizing smart nanomaterials for activatable imaging and responsive drug release. Targets is led by its Editor-in-Chief, Prof. Dr. Huangxian Ju.

MDPI’s mission and values:

As a pioneer in academic open access publishing, MDPI has been serving the scientific community since 1996. Our aim is to foster scientific exchange in all forms and across all disciplines. MDPI's guidelines for disseminating open science are based on the following values and guiding principles:

• Open Access—All our content is published in open access format and distributed under a Creative Commons License, providing free access to the latest research and allowing articles to be freely shared and content to be re-used with proper attribution;
• Timeliness and Efficiency—We rapidly publish novel research through a thorough editorial process, ensuring that a first decision is provided to authors in under 32 days and that papers are published within 7–10 days upon acceptance;
• Simplicity—We offer user-friendly tools and services on our integrated system to enhance the efficiency of our editorial process;
• High-Quality Service—We support scholars and their work by providing a range of options, such as publication in journals at mdpi.com, early publication at preprints.org, and the publication of conferences at sciforum.net, to positively impact research;
• Flexibility—We adapt and develop new tools and services to meet the changing needs of the research community, driven by feedback from authors, editors, and readers;
• Rooted in Sustainability—We ensure the long-term preservation of published papers and support the future of science through partnerships, sponsorships, and awards.

By adhering to these values and principles, MDPI remains committed to advancing scientific knowledge and promoting open-science practices.

Selected Topics:

• “Cancer Biology and Radiation Therapy: 2nd Edition”;
• “Hepatobiliary and Pancreatic Diseases: Novel Strategies of Diagnosis and Treatments”;
• “Biomarkers of Disease: Discovery and Clinical Applications”;
• “Recent Advances in Anticancer Strategies, 2nd Edition”.

Selected Articles:

Cancers
“Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment”
Cancers 2024, 16(12), 2171; https://doi.org/10.3390/cancers16122171

Current Oncology
“Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse”
Curr. Oncol. 2023, 30(2), 2322-2347; https://doi.org/10.3390/curroncol30020179

Onco
“Significance of PET/CT Imaging in Myeloma Assessment: Exploring Novel Applications beyond Osteolytic Lesion Detection and Treatment Response”
Onco 2024, 4(1), 15-36; https://doi.org/10.3390/onco4010002

Targets
“Potential of MMP-2 and MMP-9 Gelatinase Blockade as a Therapeutic Strategy in Fibrosarcoma Treatment: A Decadal Review”
Targets 2024, 2(2), 104-125; https://doi.org/10.3390/targets2020007